RT Journal Article
SR Electronic
T1 Lipid formulations of amphotericin B
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 423
OP 427
VO 65
IS 8
A2 Vidt, David G.
A1 Jones, Edward
A1 Goldman, Morton
YR 1998
UL http://www.ccjm.org/content/65/8/423.abstract
AB Amphotericin B has long been the mainstay in the treatment of systemic fungal infections, but its nephrotoxicity limits the dosage that can be used. New lipid-based forms may allow higher dosing with less nephrotoxicity. Unfortunately, these new forms are substantially more expensive, and data from randomized clinical trials of their relative efficacy are as yet limited.